We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc
ARNA

Delisted

ARNA was delisted on the 10th of March, 2022.

Back to rankings

1 hedge funds and large institutions have $0 invested in Arena Pharmaceuticals Inc in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 312 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 316 → 1 (-315)

100% less funds holding in top 10

Funds holding in top 10: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $4.86B → $0 (-$4.86B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 312

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-315
Holders Change %
-99.68%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
312
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$530M
2
BlackRock
BlackRock
New York
-$452M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$361M
4
State Street
State Street
Massachusetts
-$213M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$167M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
26
Farallon Capital Management
California
– -$48.5M -522,000 Closed
PA
27
Perceptive Advisors
New York
– -$46.5M -500,000 Closed
EMG
28
ETF Managers Group
New Jersey
– -$46.3M -498,627 Closed
UOC
29
UBS O'Connor
Illinois
– -$41.1M -442,331 Closed
Charles Schwab
30
Charles Schwab
California
– -$40.5M -436,072 Closed
Primecap Management
31
Primecap Management
California
– -$40.5M -435,870 Closed
SBH
32
Segall Bryant & Hamill
Illinois
– -$38.2M -411,550 Closed
Allianz Asset Management
33
Allianz Asset Management
Germany
– -$33.6M -361,267 Closed
Citigroup
34
Citigroup
New York
– -$32.8M -352,641 Closed
BNP Paribas Asset Management
35
BNP Paribas Asset Management
France
– -$32.6M -350,856 Closed
Citadel Advisors
36
Citadel Advisors
Florida
– -$31.4M -337,629 Closed
LCM
37
Laurion Capital Management
New York
– -$31.3M -337,105 Closed
CS
38
Candriam SCA
Luxembourg
– -$30.1M -324,079 Closed
GF
39
Gabelli Funds
New York
– -$29.5M -317,145 Closed
AllianceBernstein
40
AllianceBernstein
Tennessee
– -$25.6M -275,905 Closed
Ameriprise
41
Ameriprise
Minnesota
– -$24.8M -266,885 Closed
AA
42
AQR Arbitrage
Connecticut
– -$23.4M -252,300 Closed
PBA
43
Paradigm Biocapital Advisors
New York
– -$23.4M -251,777 Closed
CS
44
Credit Suisse
Switzerland
– -$23.3M -250,553 Closed
SCM
45
Suvretta Capital Management
New York
– -$22.8M -245,800 Closed
Balyasny Asset Management
46
Balyasny Asset Management
Illinois
– -$22.8M -245,191 Closed
NIP
47
Nicholas Investment Partners
California
– -$22.2M -239,119 Closed
Deutsche Bank
48
Deutsche Bank
Germany
– -$22.2M -239,093 Closed
SAM
49
Sectoral Asset Management
Quebec, Canada
– -$21.4M -230,043 Closed
N
50
Natixis
France
– -$21.4M -230,000 Closed
1
2
3 4 5

ARNA Hedge Fund Activity: Q1 2022 in Review

1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q1 2022, worth a combined $0 — down 100% from $4.86B a quarter earlier.

Sellers outnumbered buyers: 312 funds closed out of ARNA and 0 opened new positions — a net loss of 312 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $530M sold.

  • 1 institutional investor held Arena Pharmaceuticals Inc (ARNA) as of Q1 2022, down from 316 in Q4 2021.
  • Funds reported $0 of Arena Pharmaceuticals Inc stock for Q1 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Arena Pharmaceuticals Inc positions in Q1 2022 and 312 closed out, a net change of -312 holders.
  • The largest Arena Pharmaceuticals Inc seller in Q1 2022 was Vanguard Group, an estimated $530M sold.

Based on aggregated 13F filings for Q1 2022.